Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

Cited by (759)

Items 301–400 of 759

1. Genetic mismatch affects the immunosuppressive properties of mesenchymal stem cells in vitro and their ability to influence the course of collagen-induced arthritis
   C. Sullivan, J. Murphy, M. Griffin, R. Porter, C. Evans, C. O’Flatharta, G. Shaw, F. Barry · 2012 · Arthritis Research & Therapy
2. Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab
   D. Hoshi, A. Nakajima, E. Inoue, Kumi Shidara, E. Sato, M. Kitahama, Y. Seto, E. Tanaka, W. Urano, N. Ichikawa et al. · 2012 · Modern Rheumatology
3. Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.
   B. Betts, E. S. St Angelo, Michael G. Kennedy, James W. Young · 2011 · Blood
4. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis
   G. Jones · 2010 · Expert Review of Clinical Immunology
5. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice
   J. Kaufmann, E. Feist, A. Roske, W. Schmidt · 2013 · Clinical Rheumatology
6. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials
   L. Kristensen, A. Jakobsen, E. Bartels, P. Geborek, H. Bliddal, T. Saxne, B. Danneskiold-Samsøe, R. Christensen · 2011 · Scandinavian Journal of Rheumatology
7. Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
   A. Abuhelwa, A. Hopkins, M. Sorich, S. Proudman, D. J. Foster, M. Wiese · 2020 · Scientific Reports
8. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA
   F. Iannone, G. Ferraccioli, Luigi Sinigaglia, E. Favalli, P. Sarzi-Puttini, F. Atzeni, Roberto Gorla, C. Bazzani, M. Govoni, I. Farina et al. · 2018 · Clinical Rheumatology
9. Management of arthropathy in inflammatory bowel diseases
   Rosario Peluso, Francesco Manguso, Maria Vitiello, Salvatore Iervolino, Matteo Nicola Dario Di Minno · 2014 · Therapeutic Advances in Chronic Disease
10. Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature
    O. Shovman, Y. Shoenfeld, P. Langevitz · 2014 · Immunologic research
11. The role of tocilizumab in the management of rheumatoid arthritis
    Zoe R. Ash, Paul Emery · 2012 · Expert Opinion on Biological Therapy
12. Placebo Response in Rheumatoid Arthritis Clinical Trials
    Katie Bechman, Mark Yates, Sam Norton, Andrew Paul Cope, James Benjamin Galloway · 2019 · The Journal of Rheumatology
13. MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy
    K. Shiozawa, T. Yamane, M. Murata, R. Yoshihara, K. Tsumiyama, S. Imura, S. Shiozawa · 2016 · Arthritis Research & Therapy
14. IL-27 Activates Human Trophoblasts to Express IP-10 and IL-6: Implications in the Immunopathophysiology of Preeclampsia
    Nanlin Yin, Hua Zhang, Xin Luo, Yubin Ding, Xiaoqiu Xiao, Xiru Liu, Nan Shan, Xuemei Zhang, Qinyin Deng, Baimei Zhuang et al. · 2014 · Mediators of Inflammation
15. Allogeneic Murine Mesenchymal Stem Cells: Migration to Inflamed Joints In Vivo and Amelioration of Collagen Induced Arthritis When Transduced to Express CTLA4Ig
    C. Sullivan, F. Barry, T. Ritter, C. O’Flatharta, L. Howard, G. Shaw, I. Anegon, M. Murphy · 2013 · Stem Cells and Development
16. Sequential use of biologic therapy in rheumatoid arthritis
    M. Buch · 2010 · Current Opinion in Rheumatology
17. Intensive therapy and remissions in rheumatoid arthritis: a systematic review
    C. Hughes, D. Scott, F. Ibrahim, On Behalf Of The Faith Investigators · 2018 · BMC Musculoskeletal Disorders
18. Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs
    Ennio Giulio Favalli, Serena Bugatti, Martina Biggioggero, Roberto Felice Caporali · 2014 · BioMed Research International
19. Tocilizumab: A Novel Humanized Anti-Interleukin 6 Receptor Antibody for the Treatment of Patients with Rheumatoid Arthritis
    R. Alten · 2011 · Therapeutic Advances in Musculoskeletal Disease
20. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study
    N. Nishimoto, N. Takagi · 2010 · Modern Rheumatology
21. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
    Linda L Hushaw, Ray Sawaqed, G. Sweis, J. Reigle, Anjali Gopal, D. Brandt, Nadia Sweis, J. Curran, T. Niewold, N. Sweiss · 2010 · Therapeutics and Clinical Risk Management
22. Biologic Therapies for Autoimmune and Connective Tissue Diseases.
    Rachel M Wolfe, D. Ang · 2017 · Immunology and allergy clinics of North America
23. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison
    P. Baji, M. Péntek, L. Czirják, Z. Szekanecz, G. Nagy, L. Gulácsi, V. Brodszky · 2014 · European Journal of Health Economics
24. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)
    S. Ohta, T. Tsuru, K. Terao, S. Mogi, M. Suzaki, Eisuke Shono, Y. Ishida, Eriko Tarumi, M. Imai · 2013 · Journal of clinical pharmacology
25. Terpenes as possible drugs for the mitigation of arthritic symptoms - A systematic review.
    Alexandra M. S. Carvalho, L. Heimfarth, K. Santos, A. Guimarães, L. Picot, J. Almeida, J. Quintans, L. Quintans-Júnior · 2019 · Phytomedicine
26. The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review
    M. Nurmohamed, E. Choy, S. Lula, B. Kola, R. Demasi, P. Accossato · 2018 · Drug Safety
27. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
    E. Choy, R. Caporali, R. Xavier, B. Fautrel, R. Sanmartí, M. Bao, C. Bernasconi, A. Pethö-Schramm · 2017 · Rheumatology
28. Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis
    Y. Kawaguchi · 2017 · Journal of Scleroderma and Related Disorders
29. Comparison of Synovial Fluid Cytokine Levels between Traumatic Knee Injury and End-Stage Osteoarthritis
    Marcelo B. P. Siqueira, S. Frangiamore, A. Klika, Nicholas D Gajewski, W. Barsoum, C. Higuera · 2016 · The journal of knee surgery
30. Marked Independent Relationship between Circulating Interleukin-6 Concentrations and Endothelial Activation in Rheumatoid Arthritis
    P. Dessein, A. Solomon, A. Woodiwiss, G. Norton, L. Tsang, M. González-Gay · 2013 · Mediators of Inflammation
31. Novel targeted therapies for autoimmunity
    E. William St. Clair · 2009 · Current Opinion in Immunology
32. Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview
    H. Rezaee, Fariba Pourkarim, Samira Pourtaghi-anvarian, Taher Entezari-Maleki, Touraj Asvadi-Kermani, Masoud Nouri-vaskeh · 2021 · Pharmacology Research & Perspectives
33. Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab
    H. Corominas, C. Alegre, J. Narváez, C. Fernández-Cid, V. Torrente-Segarra, M. Gómez, F. M. Pan, R. Morlà, F. Martinez, A. Gómez-Centeno et al. · 2019 · Medicine
34. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis
    M. Soubrier, J. Pei, F. Durand, L. Gullestad, A. John · 2016 · Rheumatology and Therapy
35. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
    G. W. Naerr, P. Rein, C. Saely, H. Drexel · 2016 · Vascular pharmacology
36. Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
    A. Ogata, T. Atsumi, T. Fukuda, Y. Hirabayashi, M. Inaba, N. Ishiguro, M. Kai, D. Kawabata, D. Kida, H. Kohsaka et al. · 2015 · Arthritis care & research
37. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.
    J. Carlson, S. Ogale, F. Dejonckheere, S. Sullivan · 2015 · Value in Health
38. IL-17 in the Rheumatologist’s Line of Sight
    Marie‐Elise Truchetet, M. Djavad Mossalayi, Katia Boniface · 2013 · BioMed Research International
39. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index
    S. Kawashiri, A. Kawakami, N. Iwamoto, K. Fujikawa, T. Aramaki, M. Tamai, S. Yamasaki, H. Nakamura, Y. Ueki, K. Migita et al. · 2011 · Modern Rheumatology
40. Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis
    Sohita Dhillon · 2013 · BioDrugs
41. Diretrizes para o tratamento da artrite reumatoide
    Licia Maria Henrique da Mota, B. A. Cruz, C. Brenol, I. A. Pereira, Lucila Stange Rezende-Fronza, M. B. Bértolo, Max Vitor Carioca Freitas, N. D. da Silva, P. Louzada-Junior, Rina Dalva Neubarth Giorgio et al. · 2013 · Revista Brasileira de Reumatologia
42. Tocilizumab Treatment Decreases Circulating Myeloid Dendritic Cells and Monocytes, 2 Components of the Myeloid Lineage
    C. Richez, T. Barnetche, Liliane Khoryati, P. Duffau, M. Kostine, C. Contin-Bordes, P. Blanco, T. Schaeverbeke · 2012 · Journal of Rheumatology
43. Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review
    Manoj Khokhar, Sangita Dey, S. Tomo, Mariusz Jaremko, Abdul-Hamid M. Emwas, R. K. Pandey · 2024 · ACS Pharmacology & Translational Science
44. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
    N. Ruperto, H. Brunner, A. Ramanan, G. Horneff, R. Cuttica, M. Henrickson, J. Antón, A. Boteanu, I. Penadés, K. Minden et al. · 2021 · Rheumatology
45. Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism
    Fatima Iqbal, W. S. Baker, Madiha I. Khan, S. Thukuntla, Kevin McKinney, N. Abate, Demidmaa R. Tuvdendorj · 2017 · British Journal of Pharmacology
46. Role of Bcl‐3 in the Development of Follicular Helper T Cells and in the Pathogenesis of Rheumatoid Arthritis
    K. Meguro, Kotaro Suzuki, J. Hosokawa, Y. Sanayama, Shigeru Tanaka, S. Furuta, K. Ikeda, Hiroaki Takatori, A. Suto, A. Sakamoto et al. · 2015 · Arthritis & Rheumatology
47. IL-6–targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function
    C. Speake, Tania Habib, Katharina Lambert, C. Hundhausen, Sandra M Lord, M. Dufort, S. Skinner, Alex Hu, Mackenzie Kinsman, Britta E. Jones et al. · 2022 · JCI Insight
48. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study
    N. Ishiguro, T. Atsumi, M. Harigai, T. Mimori, N. Nishimoto, T. Sumida, T. Takeuchi, Yoshiya Tanaka, A. Nakasone, N. Takagi et al. · 2017 · Modern Rheumatology
49. Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis
    P. Welsh, K. Tuckwell, I. Mcinnes, N. Sattar · 2016 · Atherosclerosis
50. Inhibition of the Interleukin-6 Signaling Pathway: A Strategy to Induce Immune Tolerance
    Cheng Zhang, Xi Zhang, Xing-Hua Chen · 2014 · Clinical reviews in allergy and immunology
51. Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review
    I. Al-Shakarchi, N. Gullick, D. Scott · 2013 · Patient Preference and Adherence
52. Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
    P. Kiely, C. Deighton, J. Dixey, A. Östör · 2011 · Rheumatology
53. Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and meta-analysis of clinical trial studies
    A. Saki, Elham Rajaei, F. Rahim · 2021 · Rheumatology
54. Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
    E. Mysler, M. Caubet, Analí Lizárraga · 2021 · Open Access Rheumatology : Research and Reviews
55. Treadmill Running Ameliorates Destruction of Articular Cartilage and Subchondral Bone, Not Only Synovitis, in a Rheumatoid Arthritis Rat Model
    S. Shimomura, H. Inoue, Y. Arai, S. Nakagawa, Y. Fujii, T. Kishida, S. Ichimaru, S. Tsuchida, T. Shirai, K. Ikoma et al. · 2018 · International Journal of Molecular Sciences
56. Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis
    M. Kraakman, D. Dragoljevic, H. Kammoun, A. Murphy · 2016 · Clinical & Translational Immunology
57. Atacicept as an investigated therapy for rheumatoid arthritis
    C. Richez, M. Truchetet, T. Schaeverbeke, B. Bannwarth · 2014 · Expert Opinion on Investigational Drugs
58. Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    A. Diamantopoulos, A. Finckh, T. Huizinga, D. Sungher, L. Sawyer, D. Neto, F. Dejonckheere · 2014 · PharmacoEconomics (Auckland)
59. Bioinformatics Analysis for the Antirheumatic Effects of Huang-Lian-Jie-Du-Tang from a Network Perspective
    Haiyang Fang, Yichuan Wang, Ting-Hong Yang, Yang Ga, Yi Zhang, Run-Hui Liu, Wei-Dong Zhang, Jing Zhao · 2013 · Evidence-Based Complementary and Alternative Medicine
60. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study
    N. Nishimoto, K. Amano, Y. Hirabayashi, T. Horiuchi, T. Ishii, M. Iwahashi, M. Iwamoto, H. Kohsaka, M. Kondo, T. Matsubara et al. · 2013 · Modern Rheumatology
61. Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis
    S. Hayer, B. Niederreiter, I. Nagelreiter, J. Smolen, K. Redlich · 2010 · Annals of the Rheumatic Diseases
62. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab
    Inbal Haya Shafran, Farideh Alasti, Josef S Smolen, Daniel Aletaha · 2020 · Annals of the Rheumatic Diseases
63. A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases
    Michael A. Lyman, Vincent Lieuw, Robyn Richardson, A. Timmer, Christine Stewart, S. Granger, Richard H Woods, M. Silacci, D. Grabulovski, R. Newman · 2018 · Journal of Biological Chemistry
64. Tocilizumab in the treatment of adult rheumatoid arthritis.
    R. Sanmartí, V. Ruiz-Esquide, C. Bastida, D. Soy · 2018 · Immunotherapy
65. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
    H. Baek, M. Lim, W. Park, Sung Hwan Park, S. Shim, D. Yoo, H. Kim, S. Lee, Yun-Jong Lee, Y. Park et al. · 2018 · The Korean Journal of Internal Medicine
66. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis
    W. Reiss, J. Devenport, J. Low, George Y Wu, E. Sasso · 2015 · Rheumatology International
67. The Expanding Role of Therapeutic Antibodies
    Simonetta Salemi, Milica Marković, Gabriella Martini, Raffaele D’Amelio · 2014 · International Reviews of Immunology
68. Unmet needs in the treatment of autoimmunity: from aspirin to stem cells.
    Christopher Chang · 2014 · Autoimmunity Reviews
69. American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010.
    J. O'Dell, T. Mikuls, R. Colbert, M. Weinblatt · 2011 · Arthritis & Rheumatism
70. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
    T. Kojima, Y. Yabe, A. Kaneko, N. Takahashi, K. Funahashi, D. Kato, M. Hanabayashi, S. Asai, S. Hirabara, N. Asai et al. · 2015 · Rheumatology
71. Fatigue in Inflammatory Joint Diseases
    Grzegorz Chmielewski, Michał Stanisław Majewski, Jakub Kuna, Mateusz Mikiewicz, Magdalena Krajewska–Włodarczyk · 2023 · International Journal of Molecular Sciences
72. Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis
    Kexun Ma, Ling Li, Chunhui Liu, Ling-Ling Zhou, Xue-Ping Zhou · 2018 · Archives of medical science : AMS
73. Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study
    A. Kivitz, Thomas Wallace, E. Olech, M. Borofsky, J. Devenport, J. Pei, M. Michalska · 2016 · Rheumatology and Therapy
74. Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab).
    M. Souri, S. Mokuda, H. Inanami, T. Osaki, K. Takasugi, A. Ichinose · 2016 · Thrombosis Research
75. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study
    T. Okano, K. Inui, M. Tada, Y. Sugioka, K. Mamoto, S. Wakitani, T. Koike, Hiroaki Nakamura · 2016 · Rheumatology International
76. Management of rheumatoid arthritis in People’s Republic of China – focus on tocilizumab and patient considerations
    Geng Wang, R. Mu, Hu-Ji Xu · 2015 · International Journal of General Medicine
77. Therapeutic potential of Tregs to treat rheumatoid arthritis.
    G. Wright, H. Stauss, M. Ehrenstein · 2011 · Seminars in Immunology
78. Beware of Antibodies to Dietary Proteins in “Antigen-specific” Immunoassays! Falsely Positive Anticytokine Antibody Tests Due to Reactivity with Bovine Serum Albumin in Rheumatoid Arthritis (The Swedish TIRA Project)
    C. Sjöwall, A. Kastbom, G. Almroth, J. Wetterö, T. Skogh · 2011 · Journal of Rheumatology
79. Rheumatoid arthritis therapy: Advances from bench to bedside
    Soo-In Choi, E. Brahn · 2010 · Autoimmunity
80. The chromatin landscape of pathogenic transcriptional cell states in rheumatoid arthritis
    Kathryn Weinand, Saori Sakaue, Aparna Nathan, Anna Helena Jonsson, Fan Zhang, Gerald F. M. Watts, Majd Al Suqri, Zhu Zhu, Accelerating Medicines Partnership Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Network, Jennifer Albrecht et al. · 2024 · Nature Communications
81. Unraveling the Molecular Mechanism of Recognition of Selected Next-Generation Antirheumatoid Arthritis Inhibitors by Janus Kinase 1
    M. Sk, N. A. Jonniya, R. Roy, P. Kar · 2022 · ACS Omega
82. Novel small molecule IL‐6 inhibitor suppresses autoreactive Th17 development and promotes Treg development
    S. Aqel, E. Kraus, N. Jena, V. Kumari, M. C. Granitto, L. Mao, M. Farinas, E. Zhao, G. Perottino, W. Pei et al. · 2019 · Clinical and Experimental Immunology
83. Biological Therapies for Rheumatoid Arthritis: Progress to Date
    G. Malviya, S. Salemi, B. Laganà, A. Diamanti, R. D'Amelio, A. Signore · 2013 · BioDrugs
84. Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases
    Toshio Tanaka, Atsushi Ogata, Masashi Narazaki · 2013 · Clinical Medicine Insights Therapeutics
85. Association Between −174 Interleukin-6 Gene Polymorphism and Biological Response to Rituximab in Several Systemic Autoimmune Diseases
    G. Robledo, C. Dávila-Fajardo, A. Márquez, N. Ortego-Centeno, J. L. Callejas Rubio, E. de Ramón Garrido, J. Sánchez-Román, F. García-Hernández, R. Ríos-Férnandez, M. González-Escribano et al. · 2012 · DNA and Cell Biology
86. The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation
    Shatara V. Townes, D. Furst, Anuradha Thenkondar · 2012 · Open Access Rheumatology : Research and Reviews
87. Antibody immunosuppressive therapy in solid organ transplant
    Dusko Klipa, N. Mahmud, N. Ahsan · 2010 · mAbs
88. The Chromatin Landscape of Pathogenic Transcriptional Cell States in Rheumatoid Arthritis
    Kathryn Weinand, S. Sakaue, A. Nathan, A. Jonsson, Fan Zhang, G. Watts, Zhu Zhu, Deepak A. Rao, J. Anolik, M. Brenner et al. · 2023 · bioRxiv
89. A novel de novo activating mutation in STAT3 identified in a patient with common variable immunodeficiency (CVID).
    M. Russell, M. Pigors, Maha E. Houssen, A. Manson, D. Kelsell, H. Longhurst, N. Morgan · 2017 · Clinical Immunology
90. Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy
    X. Teitsma, J. Jacobs, M. Mokry, Michelle E. A. Borm, A. Pethö-Schramm, J. V. van Laar, J. Bijlsma, F. Lafeber · 2017 · Arthritis Research & Therapy
91. The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate
    M. Stevenson, A. Wailoo, J. Tosh, Mónica Hernández-Alava, Laura A Gibson, John W. Stevens, R. Archer, E. Simpson, Emma S. Hock, A. Young et al. · 2017 · Journal of Rheumatology
92. Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis.
    C. Mourgues, C. Henquell, Z. Tatar, B. Pereira, C. Nourisson, A. Tournadre, M. Soubrier, M. Couderc · 2016 · Joint, bone, spine : revue du rhumatisme
93. Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
    M. Schiff, B. Combe, T. Dörner, J. Kremer, T. Huizinga, M. Veenhuizen, A. Gill, W. Komocsar, P. Berclaz, R. Ortmann et al. · 2015 · RMD Open
94. Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab
    J. S. Lee, Jianmei Wang, Mitchell Martin, S. Germer, A. Kenwright, R. Benayed, O. Spleiss, A. Platt, R. Pilson, A. Hemmings et al. · 2011 · Pharmacogenetics & Genomics
95. Treadmill Running in Established Phase Arthritis Inhibits Joint Destruction in Rat Rheumatoid Arthritis Models
    Y. Fujii, H. Inoue, Y. Arai, S. Shimomura, S. Nakagawa, T. Kishida, S. Tsuchida, Y. Kamada, K. Kaihara, T. Shirai et al. · 2019 · International Journal of Molecular Sciences
96. Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis
    J. Narváez, C. Díaz-Torné, B. Magallares, M. V. Hernández, D. Reina, H. Corominas, R. Sanmartí, A. R. de la Serna, J. Llobet, J. Nolla · 2015 · PLoS ONE
97. The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis.
    A. Malaviya, J. Ledingham, Jill Bloxham, A. Bosworth, M. Buch, E. Choy, A. Cope, J. Isaacs, D. Marshall, Gary Wright et al. · 2014 · Rheumatology
98. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice
    T. Kojima, A. Kaneko, Y. Hirano, H. Ishikawa, H. Miyake, H. Takagi, Y. Yabe, T. Kato, K. Terabe, N. Fukaya et al. · 2012 · Modern Rheumatology
99. Golimumab: a new anti-TNF-α agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
    P. Voulgari · 2010 · Expert Review of Clinical Immunology
100. Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis
     Jeremy A. Schafer, Nicole K Kjesbo, P. Gleason · 2010 · Journal of Managed Care Pharmacy